BIOHAVEN LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.69 USD | -13.71% |
|
-12.29% | -16.61% |
| 05-10 | Biohaven Shares Fall as Q1 Loss Widens, Misses Estimates | MT |
| 04-25 | Biohaven Insider Bought Shares Worth $999,169, According to a Recent SEC Filing | MT |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 946.1 | 3,434 | 3,151 | - | - |
| Enterprise Value (EV) 1 | 480.7 | 3,052 | 2,743 | 2,739 | 2,674 |
| P/E ratio | -1.09 x | -7.47 x | -5.65 x | -6.11 x | -8.13 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | 252 x | 155 x | 19.4 x |
| EV / Revenue | - | - | 219 x | 135 x | 16.4 x |
| EV / EBITDA | -0.85 x | -7.11 x | -6.13 x | -5.2 x | -6.83 x |
| EV / FCF | -1.58 x | -9.12 x | -8.58 x | -5.03 x | -7.29 x |
| FCF Yield | -63.2% | -11% | -11.7% | -19.9% | -13.7% |
| Price to Book | 1.15 x | 8.11 x | 7.78 x | 8.92 x | 8.2 x |
| Nbr of stocks (in thousands) | 68,161 | 80,234 | 88,292 | - | - |
| Reference price 2 | 13.88 | 42.80 | 35.69 | 35.69 | 35.69 |
| Announcement Date | 23/03/23 | 29/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 12.5 | 20.36 | 162.7 |
| EBITDA 1 | - | -566.5 | -429.1 | -447.2 | -526.8 | -391.2 |
| EBIT 1 | - | -567.9 | -436.1 | -550.1 | -560.8 | -473.3 |
| Operating Margin | - | - | - | -4,401.03% | -2,754.12% | -290.94% |
| Earnings before Tax (EBT) 1 | - | -569.8 | -409.6 | -708.4 | -552.7 | -449.7 |
| Net income 1 | -236.4 | -570.3 | -408.2 | -529.4 | -550.4 | -456.1 |
| Net margin | - | - | - | -4,234.81% | -2,702.91% | -280.41% |
| EPS 2 | -6.940 | -12.75 | -5.730 | -6.319 | -5.845 | -4.391 |
| Free Cash Flow 1 | - | -303.8 | -334.8 | -319.8 | -544.6 | -366.6 |
| FCF margin | - | - | - | -2,558.36% | -2,674.48% | -225.39% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Announcement Date | 10/08/22 | 23/03/23 | 29/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | 16.67 | 12.5 | 12.5 |
| EBITDA 1 | - | - | - | - | - | -151.8 | -181.8 | -110.7 | -111.9 | -117 | -128.1 | -131.2 |
| EBIT 1 | -67.64 | -213.4 | -77.78 | -94.01 | -110.5 | -153.7 | -183.2 | -174.3 | -179.6 | -183.5 | -136.8 | -138.2 |
| Operating Margin | - | - | - | - | - | - | - | - | - | -1,100.89% | -1,094.39% | -1,105.86% |
| Earnings before Tax (EBT) 1 | -67.64 | -215.2 | -69.55 | -88.17 | -105.9 | -146 | -178.9 | -171.7 | -176.5 | -181.3 | -134.7 | -136.3 |
| Net income 1 | -67.64 | -201.1 | -70.49 | -90.35 | -102.6 | -144.8 | -179.5 | -162.3 | -165.7 | -168.5 | -133.3 | -135.2 |
| Net margin | - | - | - | - | - | - | - | - | - | -1,011.27% | -1,066.22% | -1,081.79% |
| EPS 2 | -1.750 | -3.320 | -1.030 | -1.320 | -1.500 | -1.810 | -2.200 | -1.990 | -2.015 | -2.030 | -1.586 | -1.572 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 09/11/22 | 23/03/23 | 12/05/23 | 31/07/23 | 14/11/23 | 29/02/24 | 09/05/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | 465 | 382 | 408 | 412 | 477 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -304 | -335 | -320 | -545 | -367 |
| ROE (net income / shareholders' equity) | - | -199% | -78.5% | -109% | -142% | -105% |
| ROA (Net income/ Total Assets) | - | -142% | -64.6% | -72% | -70.2% | -71.3% |
| Assets 1 | - | 401.9 | 632.1 | 734.8 | 783.7 | 639.7 |
| Book Value Per Share 2 | - | 12.00 | 5.280 | 4.590 | 4.000 | 4.350 |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | 6.07 | 3.05 | 4 | 8.26 | 6.41 |
| Capex / Sales | - | - | - | 32% | 40.59% | 3.94% |
| Announcement Date | 10/08/22 | 23/03/23 | 29/02/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
35.69
USD
Average target price
57.67
USD
Spread / Average Target
+61.58%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.61% | 3.15B | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- BHVN Stock
- Financials Biohaven Ltd.
